Amneal launches Brekiya – the first and only DHE autoinjector for adults with migraine with or without aura and cluster headaches

Amneal Pharmaceuticals, Inc. announced the U.S. commercial launch of Brekiya (dihydroergotamine mesylate) injection, the first and only ready-to-use dihydroergotamine (DHE) autoinjector approved for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults. The Brekiya autoinjector is now available by prescription exclusively through Walgreens Specialty Pharmacy and Sterling Specialty Pharmacy.

“We are excited to introduce Brekiya autoinjector, making this innovative therapy broadly available to healthcare providers and patients. As the first and only self-administered, ready-to-use DHE autoinjector, Brekiya offers patients the ability to treat debilitating attacks in a convenient way and avoid visits to the emergency room. With our expanding neurology portfolio, Amneal is committed to supporting providers through comprehensive education and ensuring strong patient access as we bring Brekiya autoinjector to market,” said Joe Renda, Senior Vice President, Chief Commercial Officer – Specialty.

Migraine affects approximately 43 million Americans, and about 300,000 live with cluster headache. Headache disorders are also the fourth most common reason for U.S. emergency department visits, accounting nearly for 3% of cases. There are limited treatment options available for cluster headache, and Brekiya autoinjector represents a new treatment option for this underserved population.